tupungato
tupungato / iStockphoto.com
13 February 2018Big Pharma

Warner-Lambert v Actavis: day one from the UK Supreme Court

LSIPR attended a packed UK Supreme Court yesterday for day one of a four-day hearing, with Warner-Lambert debating the role that plausibility plays in patent law. Below we provide an overview of the case and its core issues.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
18 January 2018   The UK Supreme Court has granted the UK BioIndustry Association permission to intervene in the case of Warner-Lambert Company v Generics and Actavis, which concerns the issue of ‘plausibility’.

More on this story

Big Pharma
18 January 2018   The UK Supreme Court has granted the UK BioIndustry Association permission to intervene in the case of Warner-Lambert Company v Generics and Actavis, which concerns the issue of ‘plausibility’.

More on this story

Big Pharma
18 January 2018   The UK Supreme Court has granted the UK BioIndustry Association permission to intervene in the case of Warner-Lambert Company v Generics and Actavis, which concerns the issue of ‘plausibility’.